$BCRX 1) Beat on Revenue 2) Beat on EPS 3) Raised FY22 guidance to $255-$265m 4) Early resolution to FDA pause 5) Reiterate peak sales of $1B Orledayo Obviously needed to be downgraded 😂. None of the analysts gave more than $1-2 value to the 9930 prior to the FDA pause back in April. So what is their bear case?
7
10
10 Likes